Short Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Declines By 98.2%

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a large drop in short interest in July. As of July 15th, there was short interest totaling 26,452 shares, a drop of 98.2% from the June 30th total of 1,511,367 shares. Based on an average trading volume of 67,658 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC boosted its stake in Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after acquiring an additional 67,886 shares in the last quarter. Susquehanna International Group LLP purchased a new position in shares of Enlivex Therapeutics in the third quarter worth about $57,000. Renaissance Technologies LLC lifted its stake in Enlivex Therapeutics by 99.4% during the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after acquiring an additional 156,336 shares during the period. HRT Financial LP lifted its stake in Enlivex Therapeutics by 719.4% during the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock valued at $108,000 after acquiring an additional 135,198 shares during the period. Finally, XTX Topco Ltd boosted its holdings in shares of Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after acquiring an additional 19,132 shares during the last quarter. 1.02% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ENLV. Zacks Research upgraded shares of Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research report on Friday, June 26th. HC Wainwright raised their price objective on shares of Enlivex Therapeutics from $195.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Finally, Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Enlivex Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $247.50.

Enlivex Therapeutics Price Performance

Shares of Enlivex Therapeutics stock traded down $0.16 on Friday, reaching $4.20. The company had a trading volume of 106,559 shares, compared to its average volume of 69,542. The firm has a market cap of $70.69 million, a price-to-earnings ratio of -0.51 and a beta of 1.52. The firm’s 50-day moving average price is $8.85 and its two-hundred day moving average price is $12.74. Enlivex Therapeutics has a 1 year low of $4.08 and a 1 year high of $31.50.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.